文献速递产科母胎医学

亚洲人群早孕期子痫前期生物标志物特征:多中心队列研究

First-trimester pre-eclampsia biomarker profiles in Asian population: multicenter cohort study.
PubMed 文献 · Ultrasound Obstet Gynecol · 2020-07-10

该前瞻性非干预多中心研究在7个亚洲人群的4023例单胎妊娠中,评估欧洲来源的生物标志物中位数倍数(MoM)公式对早产子痫前期风险筛查的适用性。结果显示亚洲人群MAP和PlGF的MoM值分别较基于高加索人群的预期公式低约4%和11%,UtA-PI MoM值相似,提示需调整额外因素或开发亚洲特异性公式。

要点

  • 亚洲队列MAP和PlGF的MoM值分别较欧洲公式预期值低约4%和11%,UtA-PI MoM值相似。
  • UtA-PI和PlGF的MoM值超出0.4至2.5截断范围的妊娠分别有16例(0.4%)和256例(6.4%)。
  • 质量评估显示各中心MAP MoM值持续低于预期但在10%以内,多数PlGF MoM值系统性低10%,南亚人群高37%。

核心结论

  • 亚洲与高加索女性人体测量学差异导致子痫前期筛查生物标志物MoM值存在显著差异,尤其MAP和PlGF的MoM值。
  • 若要报告可靠且一致的患者特异性早产子痫前期风险,需调整额外因素或开发亚洲特异性公式计算生物标志物MoM值。
  • 研究还证明了定期质量评估生物标志物值的重要性与必要性。

研究设计与样本

  • 前瞻性、非干预、多中心研究,纳入4023例单胎妊娠,孕11至13+6周,来自中国、香港、印度、日本、新加坡、台湾和泰国的11个招募中心。
  • 于2016年12月至2018年6月间筛查早产子痫前期,受试者签署书面知情同意。
  • 记录母体与妊娠特征,按胎儿医学基金会(FMF)标准化测量方案测量平均动脉压(MAP)、子宫动脉平均搏动指数(UtA-PI)和母体血清胎盘生长因子(PlGF)。
  • 使用已发表的FMF公式(主要基于欧洲高加索人群)将MAP、UtA-PI和PlGF转换为MoM值,公式校正孕龄和直接影响生物标志物水平的协变量。
  • 评估生物标志物MoM值变异、离散度(SD)和随时间变化的累积和检验,以识别测量值与预期分布的系统性偏差。

主要发现

  • 总筛查人群中MAP、UtA-PI和PlGF的MoM中位数(95%CI)分别为0.961(0.956-0.965)、1.018(0.996-1.030)和0.891(0.861-0.909)。
  • 该 largely 亚洲队列的MAP和PlGF MoM水平分别较基于 largely 高加索人群的正常中位数公式预期值低约4%和11%,UtA-PI MoM值相似。
  • UtA-PI和PlGF MoM值超出0.4至2.5 MoM范围(截断限)的妊娠分别有16例(0.4%)和256例(6.4%)。
  • 质量评估工具显示所有中心MAP MoM值持续低于预期,但在预期值10%以内;除一个中心外,所有中心UtA-PI MoM值在预期值10%以内。
  • 多数PlGF MoM值系统性低于预期值10%,但来自南亚人群的PlGF MoM值高37%。

关键数值与推荐

  • MAP MoM中位数0.961(95%CI 0.956-0.965),UtA-PI MoM中位数1.018(95%CI 0.996-1.030),PlGF MoM中位数0.891(95%CI 0.861-0.909)。
  • MAP和PlGF MoM值分别较欧洲公式预期值低约4%和11%,UtA-PI MoM值相似。
  • UtA-PI MoM超出0.4至2.5截断限者16例(0.4%),PlGF MoM超出者256例(6.4%)。
  • 所有中心MAP MoM值在预期值10%以内;除一个中心外UtA-PI MoM值在预期值10%以内;多数PlGF MoM值低10%,南亚人群高37%。

临床怎么用

  • 原文结论指出,若要报告可靠且一致的患者特异性早产子痫前期风险,需调整额外因素或开发亚洲特异性公式计算生物标志物MoM值。
  • 原文结论指出,研究证明了定期质量评估生物标志物值的重要性与必要性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To (i) evaluate the applicability of the European-derived biomarker multiples of the median (MoM) formulae for risk assessment of preterm pre-eclampsia (PE) in seven Asian populations, spanning the east, southeast and south regions of the continent, (ii) perform quality-assurance (QA) assessment of the biomarker measurements and (iii) establish criteria for prospective ongoing QA assessment of biomarker measurements. METHODS: This was a prospective, non-intervention, multicenter study in 4023 singleton pregnancies, at 11 to 13 + 6 weeks' gestation, in 11 recruiting centers in China, Hong Kong, India, Japan, Singapore, Taiwan and Thailand. Women were screened for preterm PE between December 2016 and June 2018 and gave written informed consent to participate in the study. Maternal and pregnancy characteristics were recorded and mean arterial pressure (MAP), mean uterine artery pulsatility index (UtA-PI) and maternal serum placental growth factor (PlGF) were measured in accordance with The Fetal Medicine Foundation (FMF) standardized measurement protocols. MAP, UtA-PI and PlGF were transformed into MoMs using the published FMF formulae, derived from a largely Caucasian population in Europe, which adjust for gestational age and covariates that affect directly the biomarker levels. Variations in biomarker MoM values and their dispersion (SD) and cumulative sum tests over time were evaluated in order to identify systematic deviations in biomarker measurements from the expected distributions. RESULTS: In the total screened population, the median (95% CI) MoM values of MAP, UtA-PI and PlGF were 0.961 (0.956-0.965), 1.018 (0.996-1.030) and 0.891 (0.861-0.909), respectively. Women in this largely Asian cohort had approximately 4% and 11% lower MAP and PlGF MoM levels, respectively, compared with those expected from normal median formulae, based on a largely Caucasian population, whilst UtA-PI MoM values were similar. UtA-PI and PlGF MoMs were beyond the 0.4 to 2.5 MoM range (truncation limits) in 16 (0.4%) and 256 (6.4%) pregnancies, respectively. QA assessment tools indicated that women in all centers had consistently lower MAP MoM values than expected, but were within 10% of the expected value. UtA-PI MoM values were within 10% of the expected value at all sites except one. Most PlGF MoM values were systematically 10% lower than the expected value, except for those derived from a South Asian population, which were 37% higher. CONCLUSIONS: Owing to the anthropometric differences in Asian compared with Caucasian women, significant differences in biomarker MoM values for PE screening, particularly MAP and PlGF MoMs, were noted in Asian populations compared with the expected values based on European-derived formulae. If reliable and consistent patient-specific risks for preterm PE are to be reported, adjustment for additional factors or development of Asian-specific formulae for the calculation of biomarker MoMs is required. We have also demonstrated the importance and need for regular quality assessment of biomarker values. Copyright © 2019 ISUOG. Published by John Wiley & Sons Ltd.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Chaemsaithong P, Sahota D, Pooh RK, et al. First-trimester pre-eclampsia biomarker profiles in Asian population: multicenter cohort study. Ultrasound Obstet Gynecol. 2020. PMID: 31671479. doi:10.1002/uog.21905

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。